“In conclusion, the application of this new technology has far-reaching implications for studying intracellular processes at the single-cell level
in vivo. Although the equipment we use in these studies has been customised to suit animal models, the instruments are essentially the same as those used in hospitals and clinics around the world. This raises the possibility that in the near future, clinicians may be able to assess retinal nerve cell death
in vivo as a method of monitoring disease progression and treatment efficacy. Whether a single snapshot or long-term
in vivo observation over many weeks is needed, the ability to visualise and track changes in cell viability offers the potential for major advances in the diagnosis and management of neurodegenerative diseases,” the scientists added.
Professor Francesca Coredeiro, lead author from University College London Institute of Ophthalmology said: "Few people realise that the retina is a direct, albeit thin, extension of the brain.
"It is entirely possible that in the future a visit to a high-street optician to check on your eyesight will also be a check on the state of your brain."
"I hope that screening for Alzheimer's will be available on the high street within five years."
She said the research could help scientists to see how the disease is progressing by comparing retinal cell death a few weeks apart.
"Currently, the biggest obstacle to research into new treatments for neurodegenerative diseases is the lack of a technique where the brain's response to new treatments can be directly assessed - this technique could potentially help overcome that."
The first patient trials to assess the technique for the eye disease will begin later this year.
Source-Medindia
GPL